Search Results
Your search for Justin F. Gainor, MD matches 9 pages
Showing 1 - 9Expert Point of View: Justin F. Gainor, MD
Discussant of the abstract on the ASTRUM-004 trial, Justin F. Gainor, MD, emphasized the significant, positive improvements in survival among patients randomly assigned to receive the PD-1 inhibitor serplulimab vs placebo. Dr. Gainor is Director of the Center for Thoracic Cancers Program, Director ...
Expert Point of View: Justin F. Gainor, MD
Justin F. Gainor, MD, Director of the Center for Thoracic Cancers Program at Massachusetts General Hospital, Boston, was invited to discuss IMpower151 and ILLUMINATE at the 2023 World Conference on Lung Cancer. IMpower151 vs IMpower150 Dr. Gainor examined why IMpower151 was negative for both...
Immunogenicity of SARS–CoV-2 Vaccines in Patients With Cancer
In a single-institution prospective cohort study (CANVAX Cohort Study) reported in the Journal of Clinical Oncology, Naranbhai and colleagues assessed the immunogenicity of SARS–CoV-2 vaccines in patients with cancer. They found that immunogenicity varied among vaccines and that both antibody...
Pralsetinib in Advanced RET Fusion–Positive NSCLC: ARROW Trial
As reported in The Lancet Oncology by Justin F. Gainor, MD, and colleagues, an interim analysis of the phase I/II ARROW trial has shown that the oral RET inhibitor pralsetinib produced high response rates in previously treated and treatment-naive patients with advanced RET fusion–positive non–small ...
Justin F. Gainor, MD, on NSCLC: Study Results on Nivolumab vs Ipilimumab, Bemcentinib Plus Pembrolizumab
Justin F. Gainor, MD, of Massachusetts General Hospital, discusses two key phase II studies on non–small cell lung cancer: nivolumab vs nivolumab plus ipilimumab in EGFR-mutant disease and the oral selective AXL inhibitor bemcentinib with pembrolizumab in advanced disease (Abstracts OA01.06 and...
Advances in Targeted Therapy for Non–Small Cell Lung Cancer
Targeted therapies for non–small cell lung cancer (NSCLC) are a hotbed of investigation. Two new targeted therapies are promising for patients with lung tumors that are either EGFR exon 20 insertions or RET-rearranged. At the 2019 ASCO Annual Meeting, attendees heard early data on therapies...
Justin F. Gainor, MD, on Non–Small Cell Lung Cancer: Clinical Activity and Tolerability of Selective RET Inhibitor
Justin F. Gainor, MD, of Massachusetts General Hospital, discusses updated findings from the ARROW study in which BLU-667, a selective RET inhibitor, demonstrated clinical activity and tolerability in patients with advanced RET fusion–positive non–small cell lung cancer (Abstract 9008).
Crizotinib Crosses Another Finish Line in Lung Cancer
Treatment of anaplastic lymphoma kinase (ALK)–positive lung cancer has been one of the great success stories in oncology in the past decade. First discovered in lung cancer in 2007, ALK rearrangements are found in 3% to 5% of patients and define a distinct molecular subgroup of the disease with...
ALK Rearrangements Are Associated With Improved Outcomes in Patients With Non‒Small Cell Lung Cancer and Brain Metastases
Compared with mutations in EGFR, KRAS, or with patients with no known mutations, ALK rearrangements were independently associated with improved survival outcomes in patients with non–small cell lung cancer (NSCLC) who received radiotherapy for brain metastases, according to the results of a...
